Clinical Trials Browser

Phase 2 × OTHER × GSK2110183 × Clear all

NCT01532700 2019-09-24

An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)

Phase 2 Completed

28 enrolled 12 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell